Oruka Therapeutics, Inc. (ORKA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.73B
Last updated: Nov 17, 2026 at 4:33 PM ET
Oruka Therapeutics, Inc. (ORKA) Statistics
Oruka Therapeutics (ORKA) has a market cap of $6.73B. Its share count is up 62.46% from a year earlier.
Total Valuation
| Market Cap | $6.73B |
|---|---|
| Latest price (Nov 17, 2026) | $96.32 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 255.69% over 52 weeks and trades 7.20% above its 50-day average.
| Beta (1Y) | 1.48 |
|---|---|
| 52-Week Change | +255.69% |
| 1-Month Change | +29.32% |
| 3-Month Change | -12.19% |
| 6-Month Change | +67.51% |
| 5-Year Change | +194.50% |
| 10-Year Change | -79.61% |
| Total Return (1Y) | +255.69% |
| Total Return (3Y CAGR) | +93.92% |
| Total Return (5Y CAGR) | +42.00% |
| Return vs SPY (1Y) | +239.33% |
| Max Drawdown (1Y) | -36.39% |
| Max Drawdown (3Y) | -77.76% |
| Sharpe Ratio (1Y) | 1.87 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $89.85 |
| 200-Day Average | $73.29 |
| 52-Week Range | $25.23 to $115.52 |
| RSI (14 Days) | 50.9 |
| Average Volume (20 Days) | 1.01M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 29.62x current liabilities.
| Current Ratio | 29.62x |
|---|---|
| Quick Ratio | 29.62x |
Returns and Efficiency
Return on equity is -12.74% and return on assets is -12.39% over the last 12 months.
| Return on Equity (ROE) | -12.74% |
|---|---|
| Return on Assets (ROA) | -12.39% |
| ROIC (5Y Average) | -18.92% |
Scores
ORKA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$163.00K |
| Operating Income | -$183.11M |
| Pretax Income | -$152.57M |
| Net Income | -$152.57M |
| Reported EPS (TTM) | -$2.11 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 97.56% of the $1.23B in total assets.
| Cash and Equivalents | $191.52M |
|---|---|
| Working Capital | $909.71M |
| Shareholder Equity | $1.20B |
| Book Value Per Share | $16.72 |
| Total Assets | $1.23B |
| Total Liabilities | $33.88M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $219.00K of capital spending, operating cash flow left -$123.86M of free cash flow.
| Operating Cash Flow | -$123.64M |
|---|---|
| Capital Expenditures | $219.00K |
| Free Cash Flow | -$123.86M |
| FCF Per Share | -$1.83 |
| Depreciation and Amortization | $163.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +83.76% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +83.76% |
Stock Splits
The last split was a 1-for-12 reverse split on Sep 3, 2024.
| Last Split Date | Sep 3, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ORKA
What is ORKA's market cap?
Oruka Therapeutics has a market cap of $6.73B.
How many shares of ORKA are outstanding?
Oruka Therapeutics has 71.59M shares outstanding. The count is up 62.46% from a year earlier.
Does ORKA pay a dividend?
No. Oruka Therapeutics does not pay a dividend.
ORKA pages: Overview, Charting, Earnings, Forecast, Statistics